Human cytochrome P-450 3A4: In vitro drug-drug interaction patterns are substrate-dependent

Drug Metabolism and Disposition

Volumn 28, Issue 3, 2000, Pages 360-366

  Wang, Regina W ^a   Newton, Deborah J ^a   Liu, Nini ^a   Atkins, William M ^b   Lu, Anthony Y H ^a,c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA NAPHTHOFLAVONE; CYTOCHROME P450 3A4; CYTOCHROME P450 REDUCTASE; MIDAZOLAM; NIFEDIPINE; TERFENADINE; TESTOSTERONE;

ALLOSTERISM; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; ENZYME ACTIVE SITE; ENZYME SUBSTRATE COMPLEX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGAND BINDING; LIVER MICROSOME; PRIORITY JOURNAL;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; HYDROXYLATION; KINETICS; MICROSOMES; MICROSOMES, LIVER; MIDAZOLAM; MIXED FUNCTION OXYGENASES; NIFEDIPINE; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY; TERFENADINE; TESTOSTERONE;

EID: 0034093628     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Ameer B and Weintraub RA (1997) Drag interactions with grapefruit juice. Clin Pharmacokinet 33:103-121.
2. Bertz RJ and Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210-258.
3. Franklin MR (1977) Inhibition of mixed-function oxidations by substrates forming reduced cytochrome P450 metabolic intermediate complex. Pharmacol Ther 2:227-245.
4. Ghosal A, Satoh H, Thomas PE, Bush E and Moore D (1996) Inhibition and kinetics of cytochrome P450 3A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metab Dispos 2-1:940-947.
5. Gillam MJ, Baba T, Kim BR, Ohmori S and Guengerich FP (1993) Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch Biochem Biophys 305:123-131.
6. Gorski JC, Hall SD, Jones DR, VandenBranden M and Wrighton SA (1994) Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A subfamily. Biochem Pharmacol 47:1643-1653.
7. Guengerich FP (1995) Human cytochrome P450 enzymes, in Cytochrome P450: Structure, Mechanism and Biochemistry (Ortiz de Montellano PR ed) pp 473-535, Plenum Press, New York.
8. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T and Waxman DJ (1986) Characterization of rat and human liver microsomal cytochrome P450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051-5060.
9. Harlow GR and Halpert JR (1998) Analysis of human cytochrome P450 3A4 cooperativity: Construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. Proc Natl Acad Sci USA 95:6636-6641.
10. Imaoka S, Imai Y, Shimada T and Funae Y (1992) Role of phospholipids in reconstituted cytochrome P450 3A forms and mechanism of their activation of catalytic activity. Biochemistry 31:6063-6069.
11. Irshaid Y, Branch RA and Adedoyin A (1996) Metabolic interactions of putative cytochrome P450 3A substrates with alternative pathways of dapsone metabolism in human liver microsomes. Drug Metab Dispos 24:164-171.
12. a, a form of cytochrome P450 purified from human fetal livers, is the 16α-hydroxylase of dehydroepiandrosterone 3-sulfate. J Biol Chem 262:13534-13537.
13. Koley AP, Buters JTM, Robinson RC, Markowitz A and Friedman FK (1995) CO binding kinetics of human cytochrome P450 3A4: Specific interaction of substrates with kinetically distinguishable conformers. J Biol Chem 270:5014-5018.
14. Koley AP, Buters JTP, Robinson RC, Markowitz A and Friedman FK (1997a) Differential mechanisms of cytochrome P450 inhibition and activation by α-naphthoflavone. J Biol Chem 272:3149-3152.
15. Koley AP, Dai R, Robinson RC, Markowitz A and Friedman FK (1997b) Differential interaction of erythromycin with cytochrome P450 3A 1/2 in the endoplasmic reticulum: A CO flash photolysis study. Biochemistry 36:3237-3241.
16. Koley AP, Robinson RC, Markowitz A and Friedman FK (1997c) Drug-drug interactions-effect of quinidine on nifedipine binding to human cytochrome P450 3A4. Biochem Pharmacol 53:455-460.
17. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ and Tracy TS (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137-4147.
18. Kronbach T, Mathys D, Umeno M. Gonzalez FJ and Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450 3A4. Mol Pharmacol 36:89-96.
19. Lee CA, Kadwell SH, Kost TA and Serbjit-Singh CJ (1995) CYP 3A4 expressed by insect cells infected with a recombinant baculovirus containing both CYP 3A4 and human NADPH-cytochrome P450 reductase is catalytically similar to human liver microsomal CYP 3A4. Arch Biochem Biophys 319:157-167.
20. Lewis DFV, Eddershaw PJ, Goldfarb PS and Tarbit MH (1996) Molecular modeling of CYP 3A4 from an alignment with CYP102-identification of key interactions between putative active site residues and CYP 3A4-specific chemicals. Xenobiotica 26:1067-1086.
21. Lin JH and Lu AYH (1997a) Inhibition of cytochrome P450 and implications in drag development. Annu Rep Med Chem 32:295-304.
22. Lin JH and Lu AYH (1997b) Role of pharmacokinetics and metabolism in drag discovery and development. Pharmacol Rev 49:403-449.
23. Wrighton SA and Stevens JC (1992) The human hepatic cytochromes P450 involved in drag metabolism. Crit Rev Toxicol 22:1-21.
24. S in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes. Arch Biochem Biophys 325:174-182.